Reports from Virginia Commonwealth University Add New Data to Findings in Monoclonal Antibodies (The Impact of Pcsk9 Modulation On Cardiovascular Outcomes: Recent Advances and the Managed Care Implications): Drugs and Therapies – Monoclonal Antibodies

2023 MAY 01 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Investigators publish new report on Drugs and Therapies - Monoclonal Antibodies. According to news reporting originating from Richmond, Virginia, by NewsRx editors, the research stated, “Cardiovascular disease (CVD) remains the leading cause of death globally. Hypercholesterolemia is a major modifiable risk factor for developing atherosclerotic CVD (ASCVD).”

Financial support for this research came from Novartis.

Our news editors obtained a quote from the research from Virginia Commonwealth University, “Although statins are the foundational evidence-based treatment option, significant gaps in care exist as approximately 5% to 30% of patients do not tolerate statin therapy. Ezetimibe provides additional, but modest, reductions in low-density lipoprotein cholesterol (LDL-C) and ASCVD risk. The PCSK9 enzyme has emerged as a viable therapeutic target, resulting in the approval of 2 monoclonal antibodies, alirocumab and evolocumab, and a small interfering RNA molecule, inclisiran, that reduce LDL-C levels by approximately 60% and 50%, respectively. Alirocumab and evolocumab were approved in 2015 and have been shown to reduce ASCVD risk in secondary prevention patients; however, the cost of therapy has been a barrier to uptake despite significant price reductions. Inclisiran is unique in that it requires administration by a healthcare professional, thus creating challenges and unknowns when it comes to implementing this drug in clinical practice.”

According to the news editors, the research concluded: “Managed care professionals have considerable experience with developing approaches to providing access to novel injectable lipid-lowering therapies, such as alirocumab and evolocumab, and with the approval of inclisiran, they now have an expanding list of such therapies to incorporate into their care plans.”

This research has been peer-reviewed.

For more information on this research see: The Impact of Pcsk9 Modulation On Cardiovascular Outcomes: Recent Advances and the Managed Care Implications. The American Journal of Managed Care, 2022;28. The American Journal of Managed Care can be contacted at: Managed Care & Healthcare Communications Llc, 666 Plainsboro Rd, Ste 300, Plainsboro, NJ 08536, USA.

The news editors report that additional information may be obtained by contacting Dave L. Dixon, Virginia Commonwealth University, Dept. of Pharmacotherapy and Outcomes Sciences, School of Pharmacy, Richmond, VA 23298, United States.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.37765/ajmc.2022.89269. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)